101
Participants
Start Date
December 19, 2022
Primary Completion Date
April 1, 2024
Study Completion Date
April 1, 2024
SEP-363856
SEP-363856 will be flexibly dosed for 8 weeks.
CBH Health, Gaithersburg
New Hope Clinical Research, Charlotte
Clinical Trials of America, LLC, Hickory
Advanced Discovery Research LLC, Atlanta
Atlanta Center for Medical Research, Atlanta
Atlanta Behavioral Research, Atlanta
Nova Psychiatry, Inc., Orlando
Larkin Behavioral Health Services, Hollywood
Premier Clinical Research Institute, Inc., Miami
Wellness Research Center, Miami
Charak Clinical Research Center, Garfield Heights
Uptown Research, Chicago
PsychCare Consultants Research, St Louis
Pillar Clinical Research, LLC, Richardson
IMA Clinical Research, Las Vegas
ProScience Research Group, Culver City
Cenexel CNS Research, Torrance
Clinical Innovations Inc., Bellflower
Synergy San Diego, Lemon Grove
CMB Clinical Trials, Santee
California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC), San Diego
Clinical Innovations, Inc, Riverside
Advanced Research Center, Inc., Anaheim
Collaborative Neuroscience Research, LLC, Garden Grove
Hassman Research Institute, Berlin
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY